The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Attenuated virus-based vaccines.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Attenuated virus-based vaccines is a key innovation area in the pharmaceutical industry
A live-attenuated vaccine uses a living but weakened version of a virus or bacteria with reduced virulence. Live-attenuated vaccines help in preventing infection by creating a strong and long-lasting immune response without causing serious disease in people with healthy immune systems
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 70+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of attenuated virus-based vaccines.
Key players in attenuated virus-based vaccines – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to attenuated virus-based vaccines
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Mitsubishi Chemical Group||200||Unlock company profile|
|Merck & Co||131||Unlock company profile|
|Sanofi||113||Unlock company profile|
|Johnson & Johnson||113||Unlock company profile|
|Grifols||83||Unlock company profile|
|Bavarian Nordic||83||Unlock company profile|
|C. H. Boehringer Sohn||81||Unlock company profile|
|Compagnie Merieux Alliance||78||Unlock company profile|
|F. Hoffmann-La Roche||73||Unlock company profile|
|Pfizer||66||Unlock company profile|
|GSK||46||Unlock company profile|
|E. Merck||44||Unlock company profile|
|AstraZeneca||43||Unlock company profile|
|US Department of Health and Human Services||39||Unlock company profile|
|UniQure||37||Unlock company profile|
|Baxter International||33||Unlock company profile|
|Valneva||32||Unlock company profile|
|Takeda Pharmaceutical||31||Unlock company profile|
|German Cancer Research Center||28||Unlock company profile|
|Commonwealth Scientific and Industrial Research Organisation||27||Unlock company profile|
|iosBio Pharma||27||Unlock company profile|
|Xiamen Innovax Biotech||25||Unlock company profile|
|Apse||25||Unlock company profile|
|Zydus Lifesciences||25||Unlock company profile|
|Zoetis||25||Unlock company profile|
|Cevec Pharmaceuticals||24||Unlock company profile|
|Genethon||24||Unlock company profile|
|PsiOxus Therapeutics||22||Unlock company profile|
|I'rom Group||19||Unlock company profile|
|Cevante Animale||19||Unlock company profile|
|Abbott Laboratories||19||Unlock company profile|
|IP Group||18||Unlock company profile|
|Centre National de la Recherche Scientifique||18||Unlock company profile|
|CSL||16||Unlock company profile|
|iNtRON Biotechnology||16||Unlock company profile|
|Avir Green Hills Biotechnology||16||Unlock company profile|
|Meiji Holdings||15||Unlock company profile|
|Kaketsuken||15||Unlock company profile|
|EyeGene||15||Unlock company profile|
|Bayer||14||Unlock company profile|
|Redbiotec||14||Unlock company profile|
|Sartorius||13||Unlock company profile|
|Accelerate Diagnostics||13||Unlock company profile|
|Calixar||13||Unlock company profile|
|Takara Holdings||13||Unlock company profile|
|AGC||12||Unlock company profile|
|Profectus BioSciences||10||Unlock company profile|
|Asahi Kasei||10||Unlock company profile|
|Changchun High-tech Industrial (Group)||9||Unlock company profile|
|GE Healthcare||9||Unlock company profile|
Source: GlobalData Patent Analytics
Merck is one of the leading patent filers of attenuated virus-based vaccines. The company has several marketed assets for measles, mumps, and rubella. Merck is also developing a product for cytomegalovirus (HHV-5) infections based on an attenuated virus. Apart from the above asset, the company has also filed patents for new developments based on attenuated vaccines.
In terms of application diversity, Kuros Biosciences is the top company, followed by Stabilitech and iosBio Pharma. By means of geographic reach, Grifols holds the top position, while Zydus Lifesciences and Cevec Pharmaceuticals are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.